#BIF17: Looking Ahead to 2018 Policy Landscape

The past year has seen a number of important changes in the legislative and policy landscape for biopharmaceutical companies of all sizes: Passage of the 21st Century Cures Act in December and PDUFA VI as part of the FDA Reauthorization Act (FDARA) in August, as well as the confirmation of Dr. Scott Gottlieb as FDA Commissioner, who has set an ambitious agenda for the agency. Continued talks on Capitol Hill on how best to fix the health insurance markets, and wider discussions about how to move